U.S. Entertainment Stock News

Rhythm Pharmaceuticals (RYTM) stock has been in focus after a cluster of catalysts, including U.S. and European approvals for IMCIVREE in acquired hypothalamic obesity, as well as first quarter revenue of US$60.11 million alongside a net loss of US$55.64 million. See our latest analysis for Rhythm Pharmaceuticals. The recent approvals and data updates appear to be feeding into Rhythm Pharmaceuticals’ share price performance, with the stock at US$94.17 and a 7 day share price return of 10.04%...

In early May 2026, Proto Labs reported first-quarter revenue of US$139.34 million and diluted earnings per share of US$0.33, issued new quarterly and full-year 2026 guidance, and confirmed leadership changes including the upcoming appointment of Bernardo Parlange as Chief Commercial Officer and the planned retirement of long-time COO Mike Kenison. Together, the stronger quarterly performance, upbeat guidance, and creation of a new global commercial leadership role highlight Proto Labs’ focus...

EverCommerce (EVCM) drew fresh investor attention after reporting first quarter 2026 results with revenue of US$147.47 million and net income of US$7.17 million, compared with a net loss a year earlier. See our latest analysis for EverCommerce. The latest results and progress on AI enabled products have coincided with building momentum in the stock, with a 30 day share price return of 9.62% and a 1 year total shareholder return of 5.28%. If EverCommerce's AI push has caught your eye, it can...

Ardelyx (ARDX) is back in focus after presenting new long term data on XPHOZAH at the National Kidney Foundation’s Spring Clinical Meetings, reinforcing the drug’s safety profile in dialysis patients with hyperphosphatemia. See our latest analysis for Ardelyx. The latest XPHOZAH data comes after a busy few weeks that included first quarter results and reiterated 2026 revenue guidance. Yet the stock has eased in the very short term with a 1-day share price return of 2.87% and a 7-day share...

Skyward Specialty Insurance Group (SKWD) has drawn fresh attention after first quarter 2026 earnings showed revenue of US$475.87 million and net income of US$49.73 million. The results reflect contributions from the Apollo acquisition. See our latest analysis for Skyward Specialty Insurance Group. At a share price of US$46.69, the stock has seen a 6.99% 7 day share price return and a 2.59% 1 day share price return around the earnings release, while the 1 year total shareholder return has...

We'd be surprised if Regions Financial Corporation ( NYSE:RF ) shareholders haven't noticed that an insider, Brian...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Shareholders in Insmed Incorporated ( NASDAQ:INSM ) had a terrible week, as shares crashed 28% to US$101 in the week...

Readers hoping to buy Flowco Holdings Inc. ( NYSE:FLOC ) for its dividend will need to make their move shortly, as the...

In the first quarter of 2026, International Bancshares Corporation reported net interest income of US$165.63 million and net income of US$102.19 million, with basic and diluted earnings per share from continuing operations of US$1.64, all modestly higher than a year earlier. The year-over-year earnings growth was supported by higher interest income on investment and loan portfolios, reduced interest expense on deposits, and ongoing efficiency efforts including AI-driven initiatives. With...

New Horizon Aircraft Ltd. has now completed a registered direct follow-on equity offering, raising approximately US$19.90 million through the sale of 9,254,889 Class A ordinary shares at US$2.15 each, at a small per-share discount, to support its hybrid-electric VTOL development and general corporate needs. This funding round, involving institutional investors and placement agent warrants, is intended to accelerate the Cavorite X7 hybrid-electric VTOL program while temporarily limiting...

Celldex Therapeutics recently reported first-quarter 2026 results, with revenue falling to US$15,000 from US$695,000 a year earlier and net loss widening to US$78.69 million, while accelerating investment in late-stage development of its lead antibody barzolvolimab. At the same time, Celldex completed Phase 3 enrollment for barzolvolimab in chronic spontaneous urticaria six months ahead of plan and raised about US$345 million in a follow-on offering, extending its funding runway for ongoing...

Shake Shack (SHAK) has been under pressure after first quarter results fell short on earnings and revenue, producing a rare operating loss as higher costs and regional disruptions weighed on profitability. See our latest analysis for Shake Shack. The sharp post earnings selloff is clear in the 7 day share price return of down 26.61% and 30 day return of down 28.87%. The 1 year total shareholder return of down 37.93% shows pressure has been building for some time, despite a new CFO appointment...

Franklin Electric (FELE) is back in focus after reporting first quarter 2026 results and reaffirming its full year net sales guidance, prompting investors to reassess the stock’s risk and income profile. See our latest analysis for Franklin Electric. At a share price of $99.34, Franklin Electric’s short term share price performance has been mixed, with the stock down 8.35% over 90 days but supported by a 1 year total shareholder return of 11.99%, suggesting momentum has cooled after earlier...

In early May 2026, Diebold Nixdorf reported first-quarter revenue of US$891.8 million and net income of US$5 million, while VyStar Credit Union expanded its partnership to adopt Diebold Nixdorf's Branch Automation Solutions and upgrade more than 200 ATMs with DN Series cash-recycling devices and advanced software features. The VyStar rollout highlights how Diebold Nixdorf’s artificial intelligence-driven managed services and analytics are being embedded deeper into client ATM networks,...

Key earnings details from Northeast Bank’s latest report Northeast Bank (NBN) posted third quarter results that highlighted year over year changes in profitability, including net interest income of US$63.07 million and net income of US$29.85 million for the period ended March 31, 2026. For the first nine months of the fiscal year, the bank reported net interest income of US$160.07 million and net income of US$73.14 million, giving investors fresh data to assess recent performance and earnings...

Ambarella recently announced that its co‑founder, president and CEO, Fermi Wang, received the inaugural 2026 IEEE Arun N. Netravali Video Analytics, Technology and Systems Award for his work in AI-powered video and edge analytics, underscoring the company’s technical contributions to this field. This recognition puts fresh attention on Ambarella’s edge AI system-on-chip platforms, highlighting how leadership in video analytics and AI processing underpins its semiconductor offering. We’ll now...

In early May 2026, Neurocrine Biosciences reported first‑quarter revenue of US$814.5 million and net income of US$197.9 million, alongside multiple clinical and real‑world updates for its endocrine and neuroscience portfolio, including CRENESSITY and a new obesity candidate NBIP‑’2118. Beyond the headline numbers, the first expert dosing algorithms and two‑year pediatric data for CRENESSITY suggest growing medical integration of the therapy in classic congenital adrenal hyperplasia care,...

Relay Therapeutics, Inc. recently reported first-quarter 2026 results showing revenue of US$3.00 million and a net loss of US$73.29 million, while outlining plans to advance its lead PI3Ka inhibitor zovegalisib with Pfizer’s atirmociclib into Phase 3 for frontline PI3Ka‑mutated, HR+/HER2- metastatic breast cancer. What stands out is that in heavily pre-treated patients, the zovegalisib triplet regimen showed an objective response rate approaching current first-line doublet therapies, which...

Procore Technologies (PCOR) is back in focus after its first quarter 2026 update, which combined higher revenue, a narrower net loss, raised full year guidance, fresh AI moves, and active share repurchases. See our latest analysis for Procore Technologies. Despite the stronger first quarter story and raised 2026 guidance, Procore Technologies' share price return is down 23.9% year to date and total shareholder return is down 26.2% over the past year. The 1 month share price return of 12.9%...

Sirius XM Holdings Inc. reported past first-quarter 2026 results, with revenue of US$2,091 million and net income of US$245 million, alongside higher basic and diluted earnings per share than a year earlier. A new advertising partnership with YouTube, allowing buyers to access YouTube’s audio inventory through Sirius XM’s adtech platform, signals a meaningful shift in how the company can monetize digital audio audiences. We’ll now examine how the YouTube ad partnership, alongside stronger...

Globant (NYSE:GLOB) is back in focus after a series of securities class action lawsuits alleged the company misled investors about its Latin American pivot, operational challenges, and subsequent restructuring. See our latest analysis for Globant. At a share price of US$39.23, Globant’s recent 1 day share price decline of 4.25% extends a weaker run, with the 30 day share price return down 9.32% and the 1 year total shareholder return down 71.65%. This suggests momentum has faded as investors...

In late April 2026, Brown-Forman Corporation announced it had realigned its U.S. control states distribution network, appointing four key distributors across 11 state-managed spirits markets while retaining existing partners in seven others. This reshaping of distributor relationships, following the end of merger discussions with Pernod Ricard, signals Brown-Forman’s focus on sharpening operational efficiency and market reach. We’ll now examine how this control states distribution overhaul...

Alvotech recently reported first-quarter 2026 results showing net income of US$1.03 million compared with US$109.68 million a year earlier, alongside a prior revenue decline tied to production slowdowns and facility improvements. Days later, the FDA completed a routine cGMP surveillance inspection of Alvotech’s Reykjavik site and issued a Form 483, which the company says involves remediable observations and supports its plan to resubmit key Biologics License Applications in 2026. We’ll now...